Clindamycin Palmitate Hydrochloride

CAS 25507-04-4 4 current records 2 historicalSmall Molecule

Who holds supplier records for Clindamycin Palmitate Hydrochloride? 4 organisations hold a current record for Clindamycin Palmitate Hydrochloride: an active US FDA Type II Drug Master File. A further 2 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: China (2), India (1) and Taiwan (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 13 Nov 2026. How we read these records

Cite as: PharmaTek, “Clindamycin Palmitate Hydrochloride: DMF and CEP holder records”, record as of 13 Nov 2026, pharmatek.co.uk/directory/api/clindamycin-palmitate-hydrochloride

Reading the evidence

  • 4 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 1 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (4)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Clindamycin Palmitate Hydrochloride. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Clindamycin Palmitate Hydrochloride sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (2)

Organisations whose Type II DMFs for Clindamycin Palmitate Hydrochloride are no longer active. These show a past filing, not current supply.

Show all 2 historical records
  • MYLAN LABORATORIES LTD
    Inactive DMF 24018 · filed Aug 2010
  • India · Inactive DMF 23115 · filed Sept 2009

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Clindamycin Palmitate Hydrochloride is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1200632).

Chemical identity

IUPAC name
[(2R,3R,4S,5R,6R)-6-[(1S,2S)-2-chloro-1-[[(2S,4R)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] hexadecanoate;hydrochloride
Canonical SMILES
CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@H]([C@H](O[C@@H]1SC)[C@@H]([C@H](C)Cl)NC(=O)[C@@H]2C[C@H](CN2C)CCC)O)O.Cl
InChIKey
GTNDZRUWKHDICY-DJHAJVGHSA-N
Synonyms
Cleocin, Clindamycin palmitate hcl, Clindamycin palmitate hydrochloride, NSC-759141, U-25,179 E, U-25179-E, U-25179E, Cleocin Pediatric, Clindamycin 2-palmitate hydrochloride, RefChem:54849, Clindamycin palmitate (hydrochloride), C34H64Cl2N2O6S

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Lincosamide Antibacterial
Physiologic effect
Decreased Sebaceous Gland Activity; Neuromuscular Blockade
Chemical structure
Lincosamides

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Clindamycin Palmitate Hydrochloride?

4 organisations hold an active US FDA Type II Drug Master File or a CEP for Clindamycin Palmitate Hydrochloride: APITORIA PHARMA PRIVATE LTD (India), CHONGQING CARELIFE PHARMACEUTICAL CO LTD (China), SCI PHARMTECH INC (Taiwan) and Zhejiang Hisoar Pharmaceutical Co., Ltd. (China). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Clindamycin Palmitate Hydrochloride Drug Master Files are active?

APITORIA PHARMA PRIVATE LTD (DMF 23436), CHONGQING CARELIFE PHARMACEUTICAL CO LTD (DMF 26791), SCI PHARMTECH INC (DMF 24917) and Zhejiang Hisoar Pharmaceutical Co., Ltd. (DMF 21896, 27276). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Clindamycin Palmitate Hydrochloride records mean?

2 organisations have only inactive Type II DMFs for Clindamycin Palmitate Hydrochloride. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

How do I qualify a Clindamycin Palmitate Hydrochloride supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Clindamycin Palmitate Hydrochloride?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.